| Project/Area Number |
17K19774
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Oral Science and related fields
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤原 尚樹 岩手医科大学, 歯学部, 准教授 (20190100)
帖佐 直幸 岩手医科大学, 歯学部, 准教授 (80326694)
|
|---|
| Project Period (FY) |
2017-06-30 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2017: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | ビスホスホネート / BRONJ / 間葉系幹細胞 / 歯学 |
|---|
| Outline of Final Research Achievements |
We tried to establish research basis for novel therapy against BRONJ with mesenchymal stem cells (MSCs)-induced anti-inflammatory macrophages.
We found that expression level of IL-10 was up-regulated in bone marrow-derived lineage-positive (Lin (+)) blood cells co-cultured with MSCs. We also found that MSCs-derived liquid factor and cell-cell adhesion between MSCs and Lin (+) blood cells synergistically increased IL-10 expression in the Lin (+) blood cells. We keep developing our research results into the establishment of novel therapy against for BRONJ.
|
| Academic Significance and Societal Importance of the Research Achievements |
ビスホスホネートbisphosphonate (BP)は、悪性腫瘍の形成に伴う高カルシウム血症、腫瘍の骨転移、ならびに骨粗鬆症において、破骨細胞の骨吸収を抑制することによりそれらの症状を改善する臨床的に有効性の高い薬剤である。しかし、近年、BP系薬剤関連顎骨壊死(bisphosphonate-related osteonecrosis of the jaw (BRONJ)が高い頻度で発生している。今回の我々の研究成果により、BRONJの新規治療戦略確立のための基盤が確立された。
|
